IP Library › Granted Patent US 10,588,895
Granted Patent B2
US 10,588,895 · App. 16/045,333 · Granted Mar 17, 2020

Quinuclidine derivatives and medicinal compositions containing the same

Inventors: Maria Dolors Fernandez Forner (Barcelona, ES); Maria Prat Quinones (Barcelona, ES); Maria Antonia Buil Albero (Barcelona, ES)
Assignee: ALMIRALL, S.A.
A61K31/439A61K9/0073A61K9/0075A61K31/4745A61K31/56A61K45/06A61K47/26C07D453/02Y10S514/826
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,588,895
App. No.
16/045,333
Granted
Mar 17, 2020
Kind
B2
Abstract

Provided is a method for treating chronic obstructive pulmonary disease or chronic bronchitis, or inhibiting bronchospasm, which method comprises use of a powder inhaler to administer to a human patient in need of such treatment an effective amount of a powder inhalant, wherein the powder inhalant comprises 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide.

Claims (13)

1. A method for treating chronic obstructive pulmonary disease or chronic bronchitis, or inhibiting bronchospasm, which method comprises use of a powder inhaler to administer to a human patient in need of such treatment an effective amount of a powder inhalant, wherein the powder inhalant comprises 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide.

2. The method of claim 1 , wherein the powder inhalant further comprises a pharmaceutically acceptable carrier or diluent.

3. The powder inhaler of claim 2 , wherein the pharmaceutically acceptable carrier or diluent of the powder inhalant is lactose.

4. The method of claim 1 , wherein the powder inhalant further comprises a β 2 agonist.

5. The method of claim 4 , wherein the powder inhalant further comprises a steroid or a phosphodiesterase IV inhibitor.

6. The method of claim 1 , wherein the powder inhalant further comprises a steroid.

7. The method of claim 6 , wherein the powder inhalant further comprises a phosphodiesterase IV inhibitor.

8. The method of claim 1 , wherein the powder inhalant further comprises a phosphodiesterase IV inhibitor.

9. The method of claim 1 further comprising administering an effective amount of a β 2 agonist.

10. The method of claim 9 further comprising administering an effective amount of a steroid or a phosphodiesterase IV inhibitor.

11. The method of claim 1 further comprising administering an effective amount of a steroid.

12. The method of claim 11 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.

13. The method of claim 1 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.